Current Status of Depression in Lung Cancer Chemotherapy Patients and Its Impact on Immune Function
Objective To explore the influencing factors of depression in lung cancer chemotherapy patients and the impact of combined depression on immune function.Methods Eighty lung cancer chemotherapy patients from January 2019 to April February 2023 were selected as the study subjects.The Hamilton Depression Scale(HAMD)was used for depression assessment,and divided into the depression group and the non depression group.The general information such as patient age and gender were collected.Logistic regression analysis were used to investigate the influ-encing factors of depression.The T lymphocyte levels between the depressive and non depressive groups were compared.Results Among 80 lung cancer chemotherapy patients,32 were complicated with depression,with a detection rate of 40.00％.There were statistically significant differences in age,education level,monthly family income,TNM stag-ing,and adverse reaction grading between the depression group and the non depression group(P＜0.05).There was no statistically significant difference in gender and place of residence between the two groups(P＞0.05).Logistic regres-sion analysis showed that primary school education level,family monthly income＜3000 yuan,TNM stage Ⅲ-Ⅳ,and grade Ⅳ adverse reactions were the influencing factors for depression in lung cancer chemotherapy patients.The dif-ferentiation determining antigen 3+(CD3+),CD4+,CD4+/CD8+in the depression group were significantly lower than those in the non depression group,and CD8+was significantly higher than those in the non depression group(P＜0.05).Conclusion The detection rate of depression in lung cancer chemotherapy patients is relatively high,and low edu-cational level and monthly family income may increase the risk of depression.Moreover,combined depression might reduce the patient's immune function.
Lung CancerChemotherapyDepression StateImmunologic Function
NETL
NSTL
万方数据
